Else Nutrition CEO Interview with Hamutal Yitzhak, BABY Up 61%

Else Nutrition

Else Nutrition Holdings (TSXV:BABY) (OTCPK:BABYF) continues to rocket up the markets this week. The food and nutrition company currently targeting infant, toddler, and children markets shows no signs of slowing down, so Rich is bringing you another interview with the company’s management.

After interviewing Else’s Director of Digital Marketing, Barak Orenstein, Rich wanted to go even higher up the ladder. Today, he’s talking with Else Nutrition’s CEO Hamutal Yitzhak, who is also a co-founder of the company. Before starting BABY, Yitzhak was the head of Infant Nutrition at Abbott Labs Israel.

Rich and Yitzhak discuss the pain point that her company is addressing in the industry.

Else Nutrition Addresses an Important Need

“[Infant formula] is a market with only two alternatives, and both of them are not good,” Yitzhak explains. “We’re the third one, and we’re bringing a superior product.”

The alternatives she’s referring to are cow-based protein infant formula and soy-based formula. Both dairy and soy are allergens, and, in fact, cow’s milk is the number one allergen for children aged five or younger.

Enter Your E-mail Address To Subscribe

* indicates required

Else Nutrition’s formula is a 100% plant-based formula. It’s derived entirely from almonds and buckwheat and contains zero GMOs, pesticides, hormones, antibiotics, gluten, and phytoestrogens.

“We’re a non-dairy, non-soy, 100% plant-based infant formula. We’re the only one that exists, so there’s no other alternative,” says Yitzhak.

She also explains that the product was created not only to fill the need for a non-diary, non-soy formula but also to provide parents a healthier option for their children. Approximately 1 in 12 families are raising their children vegan, which means there are millions of children who can benefit almost exclusively from Else’s formula.

Else’s Growth Potential

“Our first target market is the North American market,” says Yitzhak. She adds that Else Nutrition has been inundated with requests from interested parents who want to know when and where they can buy its product.

But BABY’s growth isn’t just limited to North America. The company is registered in 66 countries, with 18 patents granted and 45 patents pending.

Another factor that is likely to catapult the company to success is its management team. Yitzhak says that every member of the team brings considerable experience in the fast-moving consumer goods industry. Additionally, several members have an extensive background in childhood health and nutrition fields.

BABY’s Booming Stock Price

Rich first brought Else Nutrition to the attention of his community on October 18 when he profiled the exciting company. Since then, BABY stock has grown faster and stronger than an actual baby drinking Else Nutrition’s 100% plant-based infant formula.

The company has risen an incredible 61.3% since mid-October, almost entirely on excitement over BABY’s product portfolio and potential to control an incredibly lucrative market. The company’s share price is currently $0.50 on the TSX Venture Exchange.

The company’s real potential will likely come next spring, as it introduces its formulas to the market. Make sure to keep watching this company as it grows, and keep watching RichTV Live for more stock market news and corporate profiles.

Let us know what you think about Else Nutrition in the comments below.

Featured image: Else Nutrition

Please See Disclaimer

If You Liked This Article Click To Share


1) The author of the Article, or members of the author’s immediate household or family, do not own any securities of the companies set forth in this Article. The author determined which companies would be included in this article based on my research and understanding of the sector.

2) The Article was issued on behalf of a third party, Else Nutrition Holdings Inc. Bitrics Markets Group Inc. and/or Iman Consulting Group has or expects to receive $800 Canadian dollars from Market Jar Media Inc. for the creation and distribution of the video.

3) Statements and opinions expressed are the opinions of the author and not Bitrics Markets Group Inc., its directors or officers. The author is wholly responsible for the validity of the statements. The author was not paid by Bitrics Markets Group Inc. for this Article. Bitrics Markets Group Inc. was not paid by the author to publish or syndicate this Article. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. Bitrics Markets Group Inc. requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Bitrics Markets Group Inc. relies upon the authors to accurately provide this information and Bitrics Markets Group Inc. has no means of verifying its accuracy.

4) The Article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of the information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Bitrics Markets Group Inc.’s terms of use and full legal disclaimer as set forth here.. This Article is not a solicitation for investment. Bitrics Markets Group Inc. does not render general or specific investment advice and the information on richtvlive.com should not be considered a recommendation to buy or sell any security. Bitrics Markets Group Inc. does not endorse or recommend the business, products, services or securities of any company mentioned on Microsmallcap.com.

5) Bitrics Markets Group Inc. and its owners, members, officers, directors, partners and consultants may own shares of the profiled companies, which it may sell at any time, including as soon as it deposits such shares into its trading accounts, during our campaign of the profiled companies stock, after our campaign or at any other time. We also may buy and sell securities in the profiled companies which may cause (a) decline in the price of the profiled companies stock due to our selling activities, (b) increased volatility due to our buying and selling of the profiled companies stock and (c) permit us to make substantial profits while we are profiling each of these companies, yet may result in a diminished value to the stock for investors. for any company mentioned in the Article.